[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://www.lyell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 300, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 73, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 82734, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 66, "title": "Interim Principal Financial Officer, Principal Executive Officer, President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1021376, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 54, "title": "Chief Operating Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 750442, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 64, "title": "Founder & Scientific Advisor", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary K. Lee Ph.D.", "age": 48, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark A. Meltz J.D.", "age": 51, "title": "General Counsel & Corporate Secretary", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Tomlin", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Selby", "title": "Senior Vice President of Clinical Development Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 25.38, "open": 25.48, "dayLow": 25.2, "dayHigh": 27.23, "regularMarketPreviousClose": 25.38, "regularMarketOpen": 25.48, "regularMarketDayLow": 25.2, "regularMarketDayHigh": 27.23, "payoutRatio": 0.0, "beta": -0.146, "forwardPE": -30.761906, "volume": 105212, "regularMarketVolume": 105212, "averageVolume": 94488, "averageVolume10days": 95570, "averageDailyVolume10Day": 95570, "bid": 24.94, "ask": 26.1, "bidSize": 1, "askSize": 1, "marketCap": 548943744, "fiftyTwoWeekLow": 7.65, "fiftyTwoWeekHigh": 45.0, "allTimeHigh": 396.8, "allTimeLow": 7.65, "priceToSalesTrailing12Months": 13388.872, "fiftyDayAverage": 27.5682, "twoHundredDayAverage": 16.43505, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 272939712, "profitMargins": 0.0, "floatShares": 12162494, "sharesOutstanding": 21243954, "sharesShort": 521115, "sharesShortPriorMonth": 240730, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.024500001, "heldPercentInsiders": 0.27735, "heldPercentInstitutions": 0.51969004, "shortRatio": 5.11, "shortPercentOfFloat": 0.0295, "impliedSharesOutstanding": 21243954, "bookValue": 17.058, "priceToBook": 1.5148317, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -325660000, "trailingEps": -22.75, "forwardEps": -0.84, "lastSplitFactor": "1:20", "lastSplitDate": 1748822400, "enterpriseToRevenue": 6657.067, "enterpriseToEbitda": -1.48, "52WeekChange": 1.1215107, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 25.84, "targetHighPrice": 45.0, "targetLowPrice": 12.0, "targetMeanPrice": 29.66667, "targetMedianPrice": 32.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 319624000, "totalCashPerShare": 15.064, "ebitda": -184380992, "totalDebt": 44285000, "quickRatio": 10.026, "currentRatio": 10.296, "totalRevenue": 41000, "debtToEquity": 13.456, "revenuePerShare": 0.003, "returnOnAssets": -0.24162, "returnOnEquity": -0.75751, "grossProfits": 41000, "freeCashflow": -79681128, "operatingCashflow": -165015008, "revenueGrowth": -0.559, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -2483.5332, "financialCurrency": "USD", "symbol": "LYEL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "marketState": "CLOSED", "firstTradeDateMilliseconds": 1623936600000, "hasPrePostMarketData": true, "corporateActions": [], "postMarketTime": 1771024656, "regularMarketTime": 1771016402, "exchange": "NMS", "messageBoardId": "finmb_590661061", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.81245, "regularMarketPrice": 25.84, "postMarketChangePercent": -1.9349846, "postMarketPrice": 25.34, "postMarketChange": -0.5, "regularMarketChange": 0.460001, "regularMarketDayRange": "25.2 - 27.23", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 94488, "fiftyTwoWeekLowChange": 18.19, "fiftyTwoWeekLowChangePercent": 2.3777778, "fiftyTwoWeekRange": "7.65 - 45.0", "fiftyTwoWeekHighChange": -19.16, "fiftyTwoWeekHighChangePercent": -0.42577776, "fiftyTwoWeekChangePercent": 112.15108, "earningsTimestampStart": 1762981200, "earningsTimestampEnd": 1762981200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -22.75, "epsForward": -0.84, "fiftyDayAverageChange": -1.728199, "fiftyDayAverageChangePercent": -0.062688135, "twoHundredDayAverageChange": 9.404951, "twoHundredDayAverageChangePercent": 0.57224965, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-17", "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "displayName": "Lyell Immunopharma", "trailingPegRatio": null, "__fetch_time": "2026-02-14"}]